TK1

Thymidine kinase, cytosolic

27,822 patent compounds predicted against TK1, 15,287 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL808082	0.51	15/20
SCHEMBL808083	0.51	15/20
SCHEMBL291317	0.55	8/20
SCHEMBL2885	0.50	8/20
Triphosphate (SCHEMBL599226)	0.50	8/20
SCHEMBL148953	0.36	8/20
SCHEMBL23485	0.58	7/20
SCHEMBL762579	0.58	7/20
SCHEMBL154177	0.57	7/20
SCHEMBL288450	0.56	7/20
SCHEMBL157966	0.54	7/20
SCHEMBL774219	0.53	7/20
Triphosphate (SCHEMBL81707)	0.52	7/20
SCHEMBL709680	0.51	7/20
SCHEMBL3281	0.50	7/20
Phosphoramidic Acid (SCHEMBL109582)	0.49	7/20
SCHEMBL3478	0.49	7/20
SCHEMBL409820	0.48	7/20
SCHEMBL441127	0.48	7/20
Phosphoramidic Acid (SCHEMBL111241)	0.47	7/20

Germline variants in TK1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full TK1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to TK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer	PHASE1/PHASE2	RECRUITING
Safety, Tolerance, Pharmacokinetic and Antiviral Study of Amdoxovir in Combination With Zidovudine in Adults With HIV	PHASE1/PHASE2	COMPLETED
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers	PHASE2	WITHDRAWN
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome	PHASE2	COMPLETED
A Phase II Study of Capecitabine and Docetaxel in Previously Untreated Advanced Non-Small Cell Lung Cancer Patients	PHASE2	COMPLETED
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer	PHASE2	COMPLETED
Docetaxel Versus Docetaxel Plus Cisplatin Versus Docetaxel Plus S-1 as Second-line Chemotherapy in Metastatic Gastric Cancer	PHASE2	UNKNOWN
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer	PHASE2	UNKNOWN
Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer	PHASE1	WITHDRAWN
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	PHASE1	COMPLETED
Gene Therapy for the Treatment of Brain Tumors	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)	PHASE1	COMPLETED
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx	EARLY_PHASE1	COMPLETED
Evaluation of Thymidine Kinase Activity in the Serum of Patients With Solid Tumors	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Targeted Radiotherapy for Recurrent Prostate Cancer	nan	UNKNOWN
Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT	nan	COMPLETED
Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving Chemotherapy	nan	COMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN
124I-FIAU Imaging in EBV and KSHV Associated Cancers	nan	COMPLETED
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib	nan	COMPLETED
A Phase I Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a TK1 binder may also engage these)

Protein	Name	Similarity
P09768	—	1.000	P09768 →
P04047	—	1.000	P04047 →
P04184	—	0.999	P04184 →
Q27564	—	0.991	Q27564 →
Q9S750	—	0.989	Q9S750 →
Q6GPQ5	—	0.988	Q6GPQ5 →
P27158	—	0.988	P27158 →
Q822J8	—	0.986	Q822J8 →
O96720	—	0.986	O96720 →
B5ZCA9	—	0.986	B5ZCA9 →
Q2GEH7	—	0.986	Q2GEH7 →
Q5XI69	—	0.986	Q5XI69 →
Q27793	—	0.986	Q27793 →
Q5L5J0	—	0.985	Q5L5J0 →
A2XD35	—	0.985	A2XD35 →
P38025	—	0.985	P38025 →
Q8VVE4	—	0.985	Q8VVE4 →
C5WNV2	—	0.985	C5WNV2 →
KDM5B	Lysine-specific demethylase 5B	0.985	landscape →
B9IJ21	—	0.985	B9IJ21 →
O24396	—	0.985	O24396 →
B3S0D3	—	0.985	B3S0D3 →
F4IDQ6	—	0.985	F4IDQ6 →
Q9Z993	—	0.985	Q9Z993 →
Q41140	—	0.985	Q41140 →
O93937	—	0.985	O93937 →
Q6PE54	—	0.984	Q6PE54 →
Q7UFR1	—	0.984	Q7UFR1 →
Q9VR56	—	0.984	Q9VR56 →
P08955	—	0.984	P08955 →